Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Bacillus coagulans GBI-30, 6086 and Reduced Flatulence

Doses used in studies

CFU/day: 1 billion (median 1 billion, IQR 1 billion–1 billion) — 1 study

Safety in these studies

Overall tolerabilityReported
No treatment-related adverse events or serious adverse events were reported during the 8-week study period.
from: Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS

2 of 2 papers

Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS.
- 2009-03
- RCT · n = 44
- Postgraduate Medicine 121(2)
- - Larysa Hun
- PubMed: 19332970
- DOI: 10.3810/pgm.2009.03.1984
4 Insights on
- Reduced Flatulence
- High evidence
- Highly Cited
Improvements from baseline abdominal pain and bloating scores in the B coagulans GBI-30, 6086 group were statistically significant for all 7 weekly comparisons (P < 0.01).
Effect
Beneficial
Effect size
Moderate
Significant
Yes
Dose
once a day for 8 weeks (specific dosage not stated)
Bacillus coagulans GBI-30, 6068 decreases upper respiratory and gastrointestinal tract symptoms in healthy Mexican scholar-aged children by modulating immune-related proteins.
- 2019-11
- RCT · n = 80
- Food Research International 125
- - M. Anaya-Loyola
  - J. A. Enciso-Moreno
  - J. López-Ramos
  - G. García-Marín
  - María Y Orozco Álvarez
  - Ana M Vega-García
  - J. Mosqueda
  - D. García-Gutiérrez
  - D. Keller
  - I. Pérez-Ramírez
- PubMed: 31554075
- DOI: 10.1016/J.FOODRES.2019.108567
15 Insights on
- Reduced Flatulence
- High evidence
GanedenBC30 supplementation also significantly reduced the incidence rate of flatulence.
Effect
Beneficial
Effect size
Moderate
Significant
Yes
Dose
1 × 10^9 colony-forming units/day